Clinical Research Facility
Cullman, Alabama 35058
We've found
1 trials
at this facility
Multiple Sclerosis, Relapsing-Remitting Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
